Clopidogrel

作者: 莫小枫 | 来源:发表于2017-11-30 14:59 被阅读0次

"目录号: HY-15283

GPCR/G Protein-

Clopidogrel是口服活性的P2Y12受体阻断剂。

P2Y Receptor

相关产品

Suramin sodium salt-Clopidogrel hydrogen sulfate-Ticagrelor-MRS 2578-Prasugrel-AZD1283-N6-(4-Hydroxybenzyl)adenosine-Diquafosol tetrasodium-Denufosol tetrasodium-

生物活性

Description

Clopidogrel is a well-known P2Y12 receptor blocker.IC50 value:Target: P2Y12 receptorClopidogrel (INN) is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes. Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP). From Wikipedia

Clinical Trial

NCT01341600

University of Maryland-Food and Drug Administration (FDA)-National Cancer Institute (NCI)-National Institute of General Medical Sciences (NIGMS)

Metabolism of Clopidogrel

July 2010

NCT01503658

Seoul National University Hospital

Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel-Influence of Aspirin on the Pharmacokinetics/Pharmacodynamics of Clopidogrel

January 2012

Phase 4

NCT02185534

AstraZeneca

Bioequivalence, AUC, Cmax, Pharmacokinetics

August 2014

Phase 1

NCT02048228

Chinese PLA General Hospital

CLOPIDOGREL, POOR METABOLISM of (Disorder)

October 2014

Phase 2-Phase 3

NCT01097343

University of North Carolina, Chapel Hill

Disease Susceptibility

March 2010

Phase 2

NCT01960296

Icahn School of Medicine at Mount Sinai-Doris Duke Charitable Foundation

Clopidogrel

January 2012

Phase 2

NCT02010632

Khon Kaen University

Pharmacodynamics

August 2013

Phase 1

NCT01512485

Dr. Reddy's Laboratories Limited

Healthy

October 2006

Phase 1

NCT01493999

University of Pecs

Acute Coronary Syndrome

September 2011

Phase 4

NCT02628587

Hospital Central San Luis Potosi, Mexico

Acute Coronary Syndrome

February 2016

Phase 4

NCT01212302

Ruhr University of Bochum

Coronary Artery Disease

October 2008

NCT00724880

Catharina Ziekenhuis Eindhoven

Coronary Artery Disease

June 2006

Phase 4

NCT02411903

The Third Affiliated Hospital of Guangzhou Medical University

Cerebral Infarction-Clopidogrel,Poor Metabolism of (Disorder)

March 2015

Phase 4

NCT00799045

Laval University-Sanofi-Bristol-Myers Squibb

Migraine

October 2008

Phase 4

NCT01094275

Neil Kleiman, MD-The Methodist Hospital System

Coronary Artery Disease

January 2010

Phase 4

NCT01447563

Hospital Universitario Dr. Jose E. Gonzalez

Comparative Bioavailability of Clopidogrel Tablets

May 2008

Phase 1

NCT02054663

Ottawa Heart Institute Research Corporation

Acute Coronary Syndrome

December 2013

Phase 4

NCT02938182

First Affiliated Hospital Xi'an Jiaotong University

Migraine

October 2016

Phase 4

NCT01506713

Dr. Reddy's Laboratories Limited

Fasting

September 2006

Phase 1

NCT03039205

University of Sao Paulo-Fundação de Amparo à Pesquisa do Estado de São Paulo

Platelet Aggregation-Adenosine-Coronary Artery Disease-Kidney Dysfunction-Antiplatelet Therapy

July 1, 2017

Phase 2

NCT01621763

Dr. Reddy's Laboratories Limited

Healthy

September 2008

Phase 1

NCT01129063

Sanofi-Bristol-Myers Squibb

Healthy

March 2009

Phase 1

NCT01621750

Dr. Reddy's Laboratories Limited

Fasting

August 2008

Phase 1

NCT01706510

Rapid City Regional Hospital, Inc-AstraZeneca

Coronary Artery Disease

December 2012

Phase 4

NCT00620646

Samsung Medical Center

Clopidogrel Non-Responsiveness

February 2008

NCT00640679

Deutsches Herzzentrum Muenchen

Coronary Artery Disease

April 2008

Phase 4

NCT02060786

Ajou University School of Medicine-Dong-A Pharmaceutical

Acute Coronary Syndrome

October 2010

Phase 4

NCT00619073

University of Massachusetts, Worcester-Sanofi-Bristol-Myers Squibb

Blood Platelets-Clopidogrel

April 2008

NCT01260584

Daiichi Sankyo Inc.

Coronary Artery Disease

November 2010

Phase 4

NCT02560688

Daiichi Sankyo Inc.

Drug Interaction

December 2015

Phase 1

NCT01955642

Centre Hospitalier Universitaire de Saint Etienne-Groupe de Recherche sur la Thrombose

Brain Ischemia-Ischemic Attack

September 2013

NCT01609647

Dong-A University

Acute Coronary Syndrome

September 2012

Phase 3

NCT02048085

Medical Center of South Arkansas

Acute ST Segment Elevation Myocardial Infarction-Acute Coronary Syndrome

February 2014

Phase 4

NCT02133989

Samsung Medical Center-Yuyu Pharma, Inc.

Carotid Stenosis

June 2014

Phase 3

NCT01743014

AHEPA University Hospital-Aristotle University Of Thessaloniki

Diabetes Type 2-Diabetic Nephropathy-Vascular Disease

July 2012

Phase 4

NCT01806090

Chinese University of Hong Kong

Gastrointestinal Bleeding

February 2012

Phase 4

NCT01421706

Inje University

Healthy

July 2008

Phase 1

NCT00696566

Sheffield Teaching Hospitals NHS Foundation Trust-British Heart Foundation-University of Sheffield

Coronary Artery Disease

November 2007

Phase 1

NCT01011257

Neil Kleiman, MD-The Methodist Hospital System

Coronary Artery Disease

September 2009

Phase 4

NCT01465828

Gennaro Sardella-University of Roma La Sapienza

Acute Coronary Syndrome

October 2011

Phase 3

NCT01663038

Chong Kun Dang Pharmaceutical-Inje University

Coronary Artery Disease

December 2010

Phase 1

NCT02086903

Dong-A University

Pharmacodynamics

February 2014

Phase 3

NCT02469740

University Hospital of Limerick

Myocardial Ischemia-Coronary Artery Disease-Endothelial Dysfunction

July 2015

Phase 4

NCT01283282

Emory University

Coronary Artery Disease

January 2008

Phase 4

NCT00940784

Ronald Hoffman-Myeloproliferative Disorders-Research Consortium-National Cancer Institute (NCI)-Icahn School of Medicine at Mount Sinai

Polycythemia Vera

June 2009

Phase 2

NCT00484926

Seung-Jung Park-CardioVascular Research Foundation, Korea

Coronary Artery Disease

March 2007

Phase 4

NCT00444132

Sheba Medical Center

Clopidogrel Non-Responsiveness

March 2005

Phase 3

NCT01775839

Seoul National University Hospital

DRUG REACTIONS

January 2013

Phase 4

NCT03062462

First Affiliated Hospital of Harbin Medical University

Coronary Artery Disease-Clopidogrel, Poor Metabolism of

February 10, 2017

Phase 2-Phase 3

NCT01014624

Daiichi Sankyo Inc.

Coronary Artery Disease

February 2010

Phase 4

相关文章

  • Clopidogrel

    "目录号: HY-15283 GPCR/G Protein- Clopidogrel是口服活性的P2Y12受体阻断...

  • Ticagrelor vs Clopidogrel

    2013版ACCF/AHA STEMI患者诊疗临床指南中建议,将使用替格瑞洛的抗血小板治疗作为急诊PCI的STEM...

网友评论

    本文标题:Clopidogrel

    本文链接:https://www.haomeiwen.com/subject/exmvbxtx.html